191,429 Shares in Autolus Therapeutics plc (NASDAQ:AUTL) Bought by EntryPoint Capital LLC

EntryPoint Capital LLC purchased a new stake in Autolus Therapeutics plc (NASDAQ:AUTL) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 191,429 shares of the company’s stock, valued at approximately $450,000. EntryPoint Capital LLC owned approximately 0.07% of Autolus Therapeutics at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in AUTL. Privium Fund Management B.V. increased its position in Autolus Therapeutics by 24.8% in the 4th quarter. Privium Fund Management B.V. now owns 231,674 shares of the company’s stock valued at $544,000 after buying an additional 46,035 shares in the last quarter. Daiwa Securities Group Inc. increased its holdings in shares of Autolus Therapeutics by 55.5% during the fourth quarter. Daiwa Securities Group Inc. now owns 23,743 shares of the company’s stock valued at $56,000 after acquiring an additional 8,479 shares in the last quarter. Candriam S.C.A. acquired a new position in shares of Autolus Therapeutics during the fourth quarter worth approximately $7,500,000. HealthInvest Partners AB lifted its holdings in shares of Autolus Therapeutics by 8.4% in the 4th quarter. HealthInvest Partners AB now owns 479,644 shares of the company’s stock worth $1,060,000 after purchasing an additional 37,221 shares in the last quarter. Finally, Handelsbanken Fonder AB grew its position in Autolus Therapeutics by 30.9% in the 4th quarter. Handelsbanken Fonder AB now owns 73,300 shares of the company’s stock valued at $172,000 after purchasing an additional 17,300 shares during the period. Institutional investors and hedge funds own 72.83% of the company’s stock.

Autolus Therapeutics Price Performance

AUTL opened at $1.62 on Wednesday. Autolus Therapeutics plc has a fifty-two week low of $1.56 and a fifty-two week high of $6.48. The firm has a market capitalization of $431.07 million, a P/E ratio of -1.34 and a beta of 2.07. The company’s 50-day moving average is $2.00 and its 200 day moving average is $2.87.

Autolus Therapeutics (NASDAQ:AUTL) last posted its earnings results on Thursday, March 20th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.12. The firm had revenue of $0.03 million for the quarter, compared to the consensus estimate of $2.98 million. On average, equities research analysts expect that Autolus Therapeutics plc will post -0.94 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have commented on AUTL shares. Wells Fargo & Company decreased their price target on shares of Autolus Therapeutics from $8.00 to $6.00 and set an “overweight” rating for the company in a research note on Friday, March 21st. Needham & Company LLC reissued a “buy” rating and set a $10.00 target price on shares of Autolus Therapeutics in a research report on Monday, January 13th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $9.52.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.